Neurocrine Biosciences Inc (NBIX) Com Stk NPV (CDI)
Sell:$125.02Buy:$125.11
$1.60
(1.29%)
NASDAQ:
0.03%
0.03%Market closed | Prices delayed by at least 15 minutes
- This stock can be held in a
Stocks and Shares ISASell:$125.02
Buy:$125.11
Change:$1.60
(1.29%)
$1.60
(1.29%)Market closed | Prices delayed by at least 15 minutes
Sell:$125.02
Buy:$125.11
Change:$1.60
(1.29%)
$1.60
(1.29%)Market closed | Prices delayed by at least 15 minutes
Director deals
Listed below are trades carried out by directors and other individuals which are required to be notified to the market.
Recent deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 3 October 2024 | David Warren (Dave) BoyerChief Level Officer | Sell Regular sell transaction (market) | 1,295 | $113.66 | $147,189.70 | 377 |
| 13 September 2024 | David Warren (Dave) BoyerChief Level Officer | Sell Regular sell transaction (market) | 3,461 | $121.88 | $421,828.06 | 1,672 |
| 15 August 2024 | William H. (Bill) RastetterChairman of the Board | Sell Regular sell transaction (market) | 14,250 | $146.69 | $2,090,332.50 | 37,491 |
| 13 August 2024 | Gary A LyonsIndependent Director | Sell Option/Award related | 11,570 | $150.43 | $1,740,449.65 | 119,047 |
| 13 August 2024 | Mathew C AbernethyCFO | Sell Option/Award related | 14,100 | $150.38 | $2,120,346.72 | 31,528 |
| 13 August 2024 | Ingrid DelaetChief Level Officer | Sell Option/Award related | 3,043 | $150.13 | $456,847.11 | 6,607 |
| 13 August 2024 | Ingrid DelaetChief Level Officer | Sell Regular sell transaction (market) | 4,100 | $150.08 | $615,333.33 | 2,507 |
| 6 August 2024 | Ingrid DelaetChief Level Officer | Sell Option/Award related | 273 | $147.70 | $40,322.10 | 6,607 |
| 1 August 2024 | Darin LippoldtChief Legal/Compliance Officer | Sell Option/Award related | 2,996 | $154.01 | $461,422.95 | 39,740 |
| 1 August 2024 | Julie Smith CookeGroup Director | Sell Option/Award related | 12,632 | $153.26 | $1,936,016.95 | 18,202 |
5 most significant deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 8 January 2024 | Kevin Charles GormanCEO | Sell Option/Award related | 105,835 | $132.44 | $14,016,522.81 | 499,754 |
| 14 March 2024 | Eric S. BenevichChief Level Officer | Sell Option/Award related | 69,521 | $139.38 | $9,689,760.51 | 40,778 |
| 2 January 2024 | Kyle W. GanoChief Level Officer | Sell Option/Award related | 68,884 | $131.47 | $9,056,289.69 | 130,250 |
| 9 January 2024 | Kevin Charles GormanCEO | Sell Option/Award related | 62,023 | $134.01 | $8,311,894.50 | 499,754 |
| 28 February 2024 | Eric S. BenevichChief Level Officer | Sell Option/Award related | 53,143 | $134.69 | $7,157,729.70 | 40,616 |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.